The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1511
Ustekinumab (Stelara) for Crohn's Disease
The full article is available to subscribers Subscriber Login   

The FDA has approved the human interleukin (IL)-12 and -23 antagonist ustekinumab (Stelara – Janssen Biotech) for treatment of moderately to severely active Crohn's disease in adults who were intolerant of or whose disease was unresponsive to treatment with immunomodulators or corticosteroids, or a tumor necrosis factor (TNF) inhibitor. Ustekinumab was approved earlier for treatment of psoriasis and psoriatic arthritis.1,2

STANDARD TREATMENT — Corticosteroids are used to induce remission of Crohn's disease. Azathioprine or 6-mercaptopurine (6-MP) can be used for maintenance of remission. A TNF inhibitor alone or in combination with azathioprine or 6-MP can be used for both induction and maintenance of remission in patients with moderate to severe disease.3 The integrin receptor antagonist vedolizumab (Entyvio) can be used ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Ustekinumab (Stelara) for Crohn's Disease
Article code: 1511c
 Electronic, downloadable article - $25